Abbvie will acquire Gilgamesh's novel MDD investigational drug bretisilocin

智通财经
2025.08.26 10:29
8 月 26 日，艾伯维宣布与 Gilgamesh Pharmaceuticals 公司宣布达成一项确定性协议，将收购其一款用于治疗中度至重度抑郁症的在研候选药物 5-HT2A 受体激动剂兼 5-HT 释放剂 bretisilocin。
Source: 智通财经 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.